Publication at Faculty of Medicine in Pilsen |
2023
Abstract
For many years, operable non-small cell lung cancer has been associated with a high percentage of recurrences with a limited possibility of neo-/adjuvant treatment in the form of chemotherapy alone. However, recent years have seen great development in this field.
The first phase III studies yielded positive data for the adjuvant use of osimertinib, atezolizumab and pembrolizumab. Neoadjuvant use of nivolumab together with chemotherapy and perioperative approach with pembrolizumab and chemotherapy also brought other positive results.
The aim of this article is therefore to bring a summary of the changes and new findings in this area and to point out some of the challenges we continue to face.